Research Analysts Offer Predictions for VERA Q2 Earnings

Vera Therapeutics, Inc. (NASDAQ:VERA - Free Report) - Equities research analysts at HC Wainwright issued their Q2 2025 earnings estimates for Vera Therapeutics in a report released on Monday, May 5th. HC Wainwright analyst A. He expects that the company will post earnings per share of ($0.81) for the quarter. HC Wainwright has a "Buy" rating and a $75.00 price target on the stock. The consensus estimate for Vera Therapeutics' current full-year earnings is ($2.89) per share. HC Wainwright also issued estimates for Vera Therapeutics' FY2025 earnings at ($3.18) EPS, FY2026 earnings at ($2.32) EPS, FY2027 earnings at $0.83 EPS, FY2028 earnings at $3.30 EPS and FY2029 earnings at $5.37 EPS.

Other equities analysts have also issued reports about the stock. Wolfe Research assumed coverage on shares of Vera Therapeutics in a research report on Tuesday, February 4th. They issued an "outperform" rating and a $49.00 price objective for the company. The Goldman Sachs Group started coverage on shares of Vera Therapeutics in a research note on Tuesday, January 28th. They set a "buy" rating and a $58.00 price objective for the company. Wedbush dropped their price objective on shares of Vera Therapeutics from $34.00 to $26.00 and set a "neutral" rating on the stock in a report on Wednesday, May 7th. Guggenheim raised their target price on Vera Therapeutics from $59.00 to $61.00 and gave the stock a "buy" rating in a research note on Thursday, February 27th. Finally, JPMorgan Chase & Co. lowered their price target on Vera Therapeutics from $77.00 to $71.00 and set an "overweight" rating for the company in a research report on Tuesday, March 4th. One investment analyst has rated the stock with a hold rating, seven have issued a buy rating and two have issued a strong buy rating to the stock. According to data from MarketBeat, the company currently has an average rating of "Buy" and an average target price of $63.33.

Vera Therapeutics Stock Down 3.3%

NASDAQ:VERA traded down $0.75 during mid-day trading on Thursday, hitting $21.74. 161,645 shares of the company's stock traded hands, compared to its average volume of 775,874. The company has a fifty day moving average of $24.07 and a 200 day moving average of $34.52. The company has a debt-to-equity ratio of 0.17, a quick ratio of 13.76 and a current ratio of 13.76. Vera Therapeutics has a twelve month low of $18.53 and a twelve month high of $51.61. The company has a market capitalization of $1.39 billion, a P/E ratio of -8.33 and a beta of 1.28.

Vera Therapeutics (NASDAQ:VERA - Get Free Report) last announced its earnings results on Thursday, May 8th. The company reported ($0.81) earnings per share for the quarter, missing the consensus estimate of ($0.75) by ($0.06). During the same quarter in the prior year, the business posted ($0.56) EPS.

Hedge Funds Weigh In On Vera Therapeutics

A number of hedge funds have recently bought and sold shares of VERA. Huntington National Bank purchased a new position in shares of Vera Therapeutics during the 4th quarter valued at approximately $26,000. Summit Investment Advisors Inc. raised its position in Vera Therapeutics by 16.0% during the fourth quarter. Summit Investment Advisors Inc. now owns 4,639 shares of the company's stock worth $196,000 after acquiring an additional 639 shares during the period. AlphaQuest LLC purchased a new position in Vera Therapeutics during the fourth quarter valued at $34,000. Alliancebernstein L.P. lifted its holdings in Vera Therapeutics by 2.0% during the fourth quarter. Alliancebernstein L.P. now owns 40,350 shares of the company's stock valued at $1,706,000 after purchasing an additional 800 shares in the last quarter. Finally, E Fund Management Co. Ltd. grew its position in shares of Vera Therapeutics by 22.3% in the fourth quarter. E Fund Management Co. Ltd. now owns 6,203 shares of the company's stock valued at $262,000 after purchasing an additional 1,130 shares during the period. Hedge funds and other institutional investors own 99.21% of the company's stock.

Vera Therapeutics Company Profile

Vera Therapeutics, Inc, a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase III clinical trial for patients with immunoglobulin A nephropathy; and for treatment of lupus nephritis that is in Phase II clinical trial.